Regarding available pharmacotherapy to facilitate weight reduction (as distinct from lifestyle intervention programs), in the STEP 1 trial of adults, without diabetes, after 68 weeks 86.4% of the GLP-1 (semaglutide) group lost at least 5% on baseline weight, compared with 31.5% for placebo. This evidence concerns the gene GLP1R and diabetes mellitus.